X4 Pharmaceuticals gets second Nasdaq compliance period until Aug 11, 2025 for bid price rule

X4 Pharmaceuticals, Inc

Closing bid price of XFOR common stock below $1 for 32 consecutive business days as of Aug 13, 2024.
Initial 180-day compliance period ended Feb 10, 2025; Nasdaq granted additional 180 days to Aug 11, 2025.
Company may effect a reverse stock split to regain compliance if necessary.
Failure to comply by Aug 11, 2025 may lead to delisting and an appeal process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.